| Overview |
| bs-12679R-Cy5 |
| VAC14 Polyclonal Antibody, Cy5 Conjugated |
| IF(ICC) |
| Human, Mouse, Rat |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human VAC14 |
| 1-50/782 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 55697 |
| Q08AM6 |
| ArPIKfyve; FLJ10305; FLJ36622; FLJ46582; MGC149815; MGC149816; OTTHUMP00000174908; Protein VAC14 homolog; Tax1 (human T cell leukemia virus type I) binding protein 1; Tax1 (human T cell leukemia virus type I) binding protein 2; Tax1 binding protein 2; Tax1-binding protein 2; TAX1BP2; TRX; VAC 14; vac14; Vac14 homolog (S. cerevisiae); Vac14 homolog; VAC14_HUMAN. |
| The content of phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2) in endosomal membranes changes dynamically with fission and fusion events that generate or absorb intracellular transport vesicles. VAC14 is a component of a trimolecular complex that tightly regulates the level of PtdIns(3,5)P2. Other components of this complex are the PtdIns(3,5)P2-synthesizing enzyme PIKFYVE (MIM 609414) and the PtdIns(3,5)P2 phosphatase FIG4 (MIM 609390). VAC14 functions as an activator of PIKFYVE (Sbrissa et al., 2007 [PubMed 17556371]).[supplied by OMIM, Feb 2010] |
| Application Dilution |
| IF(ICC) |
1:50-200 |
Powered by Bioz